Blis MD review

Blis MD publishes peptide offers and a 29-state list, but monthly, per-session and one-time listings describe different prices and units. Its product pages add NAD⁺ at $249 and sermorelin at $179 as one-time purchases without a stated supply duration. A specific dispensing pharmacy, treating legal entity and complete renewal and cancellation contract remain unconfirmed.

Blis MD describes a Florida virtual clinic for weight loss, hormones, sexual health and peptides. Its comparison table includes sermorelin, NAD⁺, BPC-157, CJC-1295/ipamorelin, PT-141 and glutathione; BPC-157 and CJC were not among the loaded shop listings, so the table does not establish current dispensability. The FAQ lists 29 states, no insurance acceptance and HSA/FSA payments subject to plan rules. It describes adult products without a numeric minimum age.

Public pages offer a free consultation and say patients are charged only if approved. Homepage wording also says no consultation is required, while the footer requires prescription consultation. About describes a virtual clinic, but Pricing mentions in-person or virtual visits; confirm the actual pathway. Plans advertise support and monitoring without establishing required labs or their cost. Product pages advertise free shipping and clinician review. The medical director, treating legal entity and specific dispensing pharmacy remain unnamed; generic pharmacy claims do not independently verify credentials.

Pricing quotes NAD⁺ from $199/month, sermorelin from $179/month, PT-141 from $129/month and glutathione from $99/month. The Peptides table instead lists NAD⁺ IV/IM $249/session, glutathione IV/IM $99/session, sermorelin SC $249/month and PT-141 SC $149/month.

The shop adds NAD⁺ $249 and sermorelin $179, each confirmed on product pages as a one-time purchase, plus glutathione $229 and PT-141 injection $179 or nasal spray $159. A one-time purchase or session price does not establish a monthly supply. Confirm route, quantity, prescribed duration, full charge and renewal authorization. The FAQ describes product-dependent adjustments, alternatives or refund/exchange options; it does not establish a universal guarantee or complete cancellation contract.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. The peptide and GLP-1 products are compounding-pharmacy preparations, not therapeutically equivalent to branded drugs, and the public pages do not establish a specific dispensing pharmacy, which matters because compounded sterile products are not FDA-reviewed for purity and potency the way approved drugs are. The menu needs reading by evidence tier rather than as one product class, and the price list flattens exactly that distinction. Sermorelin and the CJC-1295/ipamorelin pairing act on the growth-hormone axis: a real, well-described mechanism, with thin long-term human outcome data and no controlled trial supporting the body-composition or recovery claims. Injectable NAD⁺ has no controlled human outcome trials; the oral precursors NR and NMN are the studied forms and they demonstrate a raised blood NAD⁺ level rather than a clinical benefit. BPC-157 has essentially no controlled human outcome trials — its reputation rests on animal work and anecdote — and its availability through compounding pharmacies has moved with FDA decisions, so confirm what can actually be dispensed today. Injectable glutathione and GHK-Cu have essentially no controlled human outcome evidence either. Individual results vary.